WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Crane NXT, Co. (NYSE: CXT) ("Crane NXT" or the "Company"), a premier industrial technology company, today announced the completion of its acquisition of approximately 32% of Antares Vision S.p.A. (“Antares Vision”) on a fully diluted basis from Regolo S.p.A. (“Regolo”) and Sargas S.r.L (“Sargas”). This milestone marks the first phase of Crane NXT’s acquisition of Antares Vision. Under the terms of the definitive agreements, Crane NXT purchased this initial s ...

TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- (TSX: PFAE) Picton Mahoney Asset Management announced today that it has declared the December 2025 year-end cash distribution of $0.0887 per unit for the ETF units (“ETF Units”) of the PICTON Long Short Equity (130/30) Alternative Fund. Unitholders of record of the ETF Units, at the close of business on December 22, 2025, will receive a per-unit cash distribution payable on December 31, 2025. About Picton Mahoney Asset Management Picton Mahoney Asset Management spe ...

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. PT. A live webcast of the presentation will be accessible on the “Events” page of the BBOT website at https://investors.bbot ...

Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the placebo arm Sa ...

– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced that Parent Project Muscular Dystrophy (PPMD) will host a community webinar to share and discuss positive topline results from Capricor’s Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s investigational cell therapy for the treatment of Duche ...

TERRE HAUTE, Ind., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Hallador Energy Company (Nasdaq: HNRG) (“Hallador” or the “Company”) today announced that the Company has finalized its application into the Expedited Resource Addition Study (ERAS) program and has made deposits totaling approximately $13 million as required under the application process. The application provides an expedited pathway for up to 515 MW of natural gas generation adjacent to Hallador’s Merom Generating Station. “Finalizing our application rep ...

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on December 15, 2025, the Compensation Committee of Sutro’s Board of Directors granted stock options to purchase 24,500 shares of Sutro common stock and 2,000 restricted stock units (RSUs) to new non-executive employees. The grants were made as an inducement ...

WILMINGTON, Del., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will present at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026, at 11:15 a.m. Eastern Time. A live webcast and replay of the presentation and Q&A session will be accessible on Clover Health's investor relations website at https://investors.cloverhealth.com/. About Clover Health ...

CULVER CITY, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, unveiled major advancements across its growing digital ecosystem during its 2025 Investor Day at the NASDAQ MarketSite in New York City. Company executives shared new developments in crypto and long-term content expansion for the company’s leading game franchise ARK. During the event, Snail introduced it ...

HOUSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 5,227,275 shares of its common stock ...